| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Shares of PPD (NASDAQ:PPD) were flat in after-market trading after the company reported Q2 results.
Earnings per share were up 56.00% year over year to $0.39, which beat the estimate of $0.33.
Revenue of $1,575,000,000 rose by 55.79% year over year, which beat the estimate of $1,320,000,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Company's 52-week high was at $46.63
Company's 52-week low was at $28.00
Price action over last quarter: down 0.30%
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.
Posted In: PPD
